Perinatal EvidenceCompass
Prepopulated workbenchMED-180

Benzodiazepines

Midazolam

Benzodiazepine-class anxiolytic, sedative, anticonvulsant, or procedural agent

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Midazolam
Entity type
single-ingredient drug
Active component(s)
Midazolam
Formulation / route / interval
Oral; formulation varies
Attachment entry
Midazolam
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Not populated in v0.95
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

6 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

A-026Provisional public source

A large Korean claims cohort found small adjusted increases in overall and cardiac malformations after first-trimester benzodiazepine exposure, with a dose-response pattern.

Public-source certainty descriptor
moderate for small association; causality uncertain; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
first trimester
Comparator
benzodiazepine exposed versus unexposed
Effect or numbers carried forward

40,846 exposed among 3,094,227 pregnancies; major malformations 65.3 versus 51.4 per 1,000, adjusted RR 1.09 (1.05-1.13); heart defects 38.9 versus 27.4 per 1,000, adjusted RR 1.15 (1.10-1.21).

Limitations

Claims exposure, live-birth restriction, residual confounding by indication/severity, and limited molecule-specific precision.

Sources, citation controls, and verification state

Linked sources

PMID
35235572
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-027Provisional public source

A Quebec case-time-control study associated early-pregnancy benzodiazepine exposure with spontaneous abortion.

Public-source certainty descriptor
low-to-moderate for association; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
early pregnancy
Comparator
exposed versus matched/control intervals
Effect or numbers carried forward

Adjusted OR 1.85 (95% CI 1.61-2.12).

Limitations

Confounding by anxiety, insomnia, severity, smoking, and co-medication may remain; cannot attribute an individual loss to exposure.

Sources, citation controls, and verification state

Linked sources

PMID
31090881
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-028Provisional public source

A prospective pregnancy registry did not find an overall major-malformation increase with benzodiazepines, but was underpowered for specific agents and rare defects.

Public-source certainty descriptor
low-to-moderate; wide interval; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
first trimester
Comparator
benzodiazepine exposed versus psychiatric controls
Effect or numbers carried forward

Major malformations 3.21% among 151 exposed versus 3.46% among 902 controls; OR 0.92 (95% CI 0.35-2.41).

Limitations

Voluntary registry, modest sample, possible selection bias, and inadequate agent-specific power.

Sources, citation controls, and verification state

Linked sources

PMID
35909254
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-029Provisional public source

A 2026 cohort with robust comparison designs did not support an increased risk of offspring psychiatric disorders after prenatal benzodiazepine exposure.

Public-source certainty descriptor
moderate against a large causal psychiatric-disorder effect; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
prenatal exposure
Comparator
exposed versus unexposed, sibling and/or negative-control comparisons
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Does not resolve rare outcomes, individual molecules/doses, neonatal toxicity, or all neurodevelopmental domains.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-030Provisional public source

The 2025 joint benzodiazepine tapering guideline advises against abrupt discontinuation in a dependent patient and calls for maternal-fetal shared decision-making; lorazepam is generally preferred in pregnancy/lactation when a benzodiazepine is necessary.

Public-source certainty descriptor
guideline consensus; not a formal GRADE rating in this module
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and lactation
Comparator
supervised taper/continuation versus abrupt stop
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Taper pace and agent choice depend on indication, dependence, seizure risk, prior response, and co-sedatives.

Sources, citation controls, and verification state

Linked sources

PMID
40526204
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-067Provisional public source

FDA prescription labeling uses narrative Pregnancy and Lactation Labeling Rule sections rather than the former A/B/C/D/X letter categories.

Public-source certainty descriptor
high for US regulatory framework
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and lactation
Comparator
not applicable
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Exact labeling and revision date remain product-specific; non-US systems differ.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending